JP2007517913A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517913A5
JP2007517913A5 JP2006549626A JP2006549626A JP2007517913A5 JP 2007517913 A5 JP2007517913 A5 JP 2007517913A5 JP 2006549626 A JP2006549626 A JP 2006549626A JP 2006549626 A JP2006549626 A JP 2006549626A JP 2007517913 A5 JP2007517913 A5 JP 2007517913A5
Authority
JP
Japan
Prior art keywords
composition
subject
administered
medicament
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006549626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/001230 external-priority patent/WO2005070445A2/en
Publication of JP2007517913A publication Critical patent/JP2007517913A/ja
Publication of JP2007517913A5 publication Critical patent/JP2007517913A5/ja
Pending legal-status Critical Current

Links

JP2006549626A 2004-01-13 2005-01-13 カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物 Pending JP2007517913A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56074504P 2004-01-13 2004-01-13
US60894504P 2004-01-13 2004-01-13
US56505604P 2004-04-23 2004-04-23
PCT/US2005/001230 WO2005070445A2 (en) 2004-01-13 2005-01-13 Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same

Publications (2)

Publication Number Publication Date
JP2007517913A JP2007517913A (ja) 2007-07-05
JP2007517913A5 true JP2007517913A5 (https=) 2008-02-28

Family

ID=34812098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006549626A Pending JP2007517913A (ja) 2004-01-13 2005-01-13 カルシトニン遺伝子関連ペプチドを投与することによって急性心筋梗塞を処置するための方法およびカルシトニン遺伝子関連ペプチドを含有する組成物

Country Status (6)

Country Link
US (1) US20090023643A1 (https=)
EP (1) EP1703916A2 (https=)
JP (1) JP2007517913A (https=)
CA (1) CA2552758A1 (https=)
TW (1) TW200538148A (https=)
WO (1) WO2005070445A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976847B2 (en) 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
JP2007517911A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
AU2008310076A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag CGRP as a therapeutic agent
CA3077804C (en) 2012-01-09 2023-07-25 Serpin Pharma, Llc Peptides and methods of using same
WO2017040287A1 (en) * 2015-08-28 2017-03-09 Serpin Pharma, Llc Methods for treatment of diseases
EP3911359A4 (en) * 2018-12-21 2022-11-16 Epoqe Pharma ApS COMPOUNDS FOR USE IN INDUCITING MYOCARDIAL PERFUSION RESTORATION

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280825A (https=) * 1962-07-11
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
EP0188400B1 (de) 1985-01-16 1992-07-08 Ciba-Geigy Ag Oligopeptide sowie Zwischenprodukte und Verfahren zu ihrer Herstellung
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5190761A (en) * 1986-08-05 1993-03-02 Liburdy Robert P Electromagnetic field triggered drug and chemical delivery via liposomes
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
EP0303306B1 (en) * 1987-08-08 1993-03-10 Akzo N.V. Contraceptive implant
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
USRE37950E1 (en) * 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JPH0789876A (ja) * 1993-09-20 1995-04-04 Shiseido Co Ltd 徐放性製剤
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
JP4259610B2 (ja) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
NZ331186A (en) * 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6086582A (en) * 1997-03-13 2000-07-11 Altman; Peter A. Cardiac drug delivery system
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP1034207B1 (en) * 1997-10-03 2005-03-02 Macromed Inc. BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
DE69916031T2 (de) * 1998-01-29 2005-02-17 Poly-Med Inc. Asorbierbare mikropartikel
DE69907870T2 (de) * 1998-01-29 2004-03-04 Kinerton Ltd., Blanchardstown Verfahren zur herstellung von absorbierbaren mikropartikeln
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
EP1140014B1 (en) * 1998-12-31 2003-03-19 Alza Corporation Osmotic delivery system having space efficient piston
CA2277656C (en) * 1999-07-19 2010-04-27 Imax Corporation Image projection system
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
CN1697647A (zh) * 2002-02-01 2005-11-16 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
JP2007517911A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
CN101014285A (zh) * 2004-09-09 2007-08-08 拜尔健康护理有限责任公司 使用压缩空气的用于刺血针的阻尼系统

Similar Documents

Publication Publication Date Title
JP2007145875A5 (https=)
JP2010222367A5 (https=)
JP2013507439A5 (https=)
JP2013542247A5 (https=)
JP2010502600A5 (https=)
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
ECSP088239A (es) Composición de liberación de fármaco sostenida
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2004534850A5 (https=)
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
ECSP088240A (es) Composición de trazodona para administración una vez por día
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
JP2005524658A5 (https=)
JP2012512907A5 (https=)
CL2007001132A1 (es) Compuestos derivados de purina sustituida con otros sistemas heterociclicos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
TN2009000095A1 (en) Thiazole pyrazolopyrimidines as crf1 receptor antagonists
NZ588913A (en) Liver cancer drug
ES2569354T3 (es) Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2008002353A1 (es) Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c.